// App-Quantinova.ai

: ATIM-24. INTERIM RESULTS OF A PHASE II MULTICENTER STUDY OF THE CONDITIONALLY REPLICATIVE ONCOLYTIC ADENOVIRUS DNX-2401 WITH PEMBROLIZUMAB (KEYTRUDA) FOR RECURRENT GLIOBLASTOMA; CAPTIVE STUDY (KEYNOTE-192)

Researchers

Presenter

  • L Sue Frederick

Principal Investigators

  • Karen Gammon

  • Sheila Fulling

  • Kari Anne Rowland

  • Erin Mitchell

  • Brett Ewald

  • Frank Tufaro

  • Joanna Peterkin

Medical Centers

  • DNAtrix, Chapel Hill, NC, USA

  • DNAtrix, Sumter, SC, USA

  • DNAtrix, West Chester, PA, USA

  • DNAtrix, McKinney, TX, USA

  • Apotex Inc., Toronto, ON, Canada

  • DNAtrix, Inc., San Diego, CA, USA

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • N/A

Biomarkers

  • Gamma glutamyltransferase

Drug/Treatment

  • Pembrolizumab

  • Bevacizumab

  • Delta-24-RGD-4C

Outcome

  • N/A

Study Design

  • Multicenteric

  • Dose Escalation

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved